When Asi Naim, a severely autistic Israeli boy, started smacking his head against the wall and hurting himself in other ways, his parents tried every kind of psychiatric drug to calm him. Nothing worked.
“He was so totally out of it,” said his mother, Ricky Naim Blumenfeld. “It was scary.”
Then Asi entered a cannabis-based researchprogram at Jerusalem’s Shaarei Zedek hospital. After a period of trial and error, he started getting a dosage of cannabinoid drops that worked. Four years later, Asi loves music, being at parties, going to the movies and traveling abroad.
The same medication has helped many of the 60 autistic children enrolled in neuro-pediatrian Adi Aran’s program. Aran is now in the middle of a second, controlled study with 100 children. The end goal: approval by the U.S. Federal Drug Administration as an experimental treatment.
The agency hasn’t yet approved a botanically derived medical cannabis product. But classifying the formulation as an FDA-recognized drug would mean it’s no longer covered by the federal ban on U.S. imports of marijuana, a key step in solidifying Israel’s reputation as a global center for medical weed research, development and exports. Belgium, Netherlands, Romania, Portugal, Czech Republic, Germany and Switzerland are major potential markets for medical marijuana, says Ameri Research Inc., a U.S. market-research and consulting company.
The market for medical weed will reach $33 billion in 2024, Ameri said in an April report. That’s a threefold increase from projected sales of $10 billion this year amid growing acceptance of marijuana for pain management, multiple sclerosis, cancer, arthritis and other chronic conditions.
Israeli grower and medicinal formula developer Breath of Life Pharma, which supported the autism research, plans to apply for “investigative new drug” status from the FDA next year if the results from Aran’s trials are conclusive enough. FDA recognition would boost a company that plans to open hubs for production, cultivation and clinical trials in several countries outside the U.S., said Chief Executive Officer Tamir Gedo.
Israeli legislation to allow exports of qualified medical cannabis has passed preliminary reading in parliament and is expected to be completed next year. An inter-ministerial team said in August that sales abroad from countries already interested would add as much as 4 billion shekels ($1.1 billion) a year to the nation’s $320 billion economy.
Israel won’t be the only country selling its cannabis on the global market. Canada and the Netherlands already do so. Uruguay, which allows government-authorized medical cannabis exports, and Colombia, which in 2015 established a framework for cultivation, processing, research and development and export of medical cannabis, are expected to start sales abroad in the near future.
The Israeli government is counting on its products standing out, distinguished by agricultural technology created to make the desert bloom, such as Netafim Ltd.’s drip-irrigation system and seed company Hazera Ltd.’s specially bred crops that include tomatoes, radishes and melons.
“When Israel handed out original licenses for growing cannabis, they started with an advanced agricultural infrastructure first used to grow other leafy green vegetables and fruit,” said Scott Greiper, founding partner of Viridian Capital Advisors, a New York-based financial advisory firm dedicated to the cannabis industry.
The government team recommending export said Israeli companies must maintain high, medical-grade standards and be subject to strict supervision, with sales allowed only to countries that specifically approved Israel’s merchandise.
Still, there’s a limited window of opportunity to Israel’s advantage in the market. As other countries begin producing for their own markets, the need for imports could fall, said Saul Kaye, founder of iCAN, a company that invests in the local cannabis market.
READ THE FULL ARTICLE BELOW